NCT05680948Completed
Extended Follow-Up of the ISS T-003 Trial Volunteers (ISS T-003 EF-UP2020)
A Roll-Over Observational Study for the Extended Follow-Up of the Volunteers of the ISS T-003 Trial (ISS T-003 EF-UP2020)
Source: ClinicalTrials.gov · Last updated 27 Mar 2026
Brief summary (registry, in English)
A further extension of the follow-up of the volunteers of the ISS T-003 trial is being conducted in order to evaluate the persistence of vaccine immunogenicity as well as of the immunological and virological effects induced by the therapeutic immunization with Tat after about 10 years from vaccination.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 179 (actual)
- First submitted
- 5 Dec 2022
- Start date
- 25 Jan 2023
- Primary completion date
- 31 Dec 2023
- Lead sponsor
- Istituto Superiore di Sanità
- Diseases
- HIV
- NCT number
- NCT05680948
What you commit to
- Study type: Observational
- Participants enrolled: 179
- From 25 Jan 2023 to the primary completion date, 31 Dec 2023
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- The absence of any of the above criteria will exclude the participants from the study.
Who the study is looking for
- previous participation in the ISS T-003 EF-UP study without withdrawal of consent;
- availability to participate in the ensuing extended follow-up study;
- signed informed consent.
Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Mecru Clinical Research Unit (MeCRU) Coordinator of this site? Confirm its status | Medunsa | South Africa | Unknown status |
Related publications
This page is information, not medical advice. Discuss any trial with your doctor.